We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Study of Genzyme Oral Compound for Gaucher Disease Meets Primary Endpoint

News   Mar 02, 2009

 
Study of Genzyme Oral Compound for Gaucher Disease Meets Primary Endpoint
 
 
 

RELATED ARTICLES

Switching Embryonic Stem Cells to Neurons to Expose Drug Effects on the Developing Brain

News

A new experimental system has been designed that can rapidly assess the pathogenic effects of a drug on a baby's developing brain. The system uses embryonic stem cells reprogrammed into neurons, and offers a powerful tool for probing genetic and molecular underpinnings of drug-induced neurodevelopmental disorders.

READ MORE

Sickle Cell Drug IMR-687 Shows Promise in Clinical Trial

News

An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.

READ MORE

Patent Issued for Osteoarthritis Gene Therapy Product

News

A potentially disease-modifying therapy for osteoarthritis has reached a key milestone now that a U.S. patent has been issued for FX201, a gene-therapy product candidate based on work led by Baylor College of Medicine researchers.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE